General Announcement::Glenmark inks agreement with Canadian biotech SaNOtize to commercialize Nitric Oxide Nasal Spray

Issuer & Securities

Issuer/ Manager
GLENMARK PHARMACEUTICALS LIMITED
Securities
GLENMARK PHARM US$170M2%220628 - XS1426780125 - 4G8B
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
02-Aug-2021 14:39:06
Status
New
Announcement Sub Title
Glenmark inks agreement with Canadian biotech SaNOtize to commercialize Nitric Oxide Nasal Spray
Announcement Reference
SG210802OTHR6LL4
Submitted By (Co./ Ind. Name)
Glenmark Pharmaceuticals Limited
Designation
Company Secretary & Compliance Officer
Effective Date and Time of the event
02/08/2021 00:00:00
Description (Please provide a detailed description of the event in the box below)
Glenmark inks agreement with Canadian biotech SaNOtize to commercialize Nitric Oxide Nasal Spray for COVID-19 treatment in India and other Asian markets

Attachments

SGX_PR_02082021.pdf
Total size =337K